SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations

Cancer Research

Volumn 64, Issue 18, 2004, Pages 6700-6706

  Alley, Michael C ^a,b   Hollingshead, Melinda G ^a,b   Pacula Cox, Christine M ^a,b   Waud, William R ^c   Hartley, John A ^d   Howard, Philip W ^e   Gregson, Stephen J ^e   Thurston, David E ^e   Sausville, Edward A ^a,b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SOUTHERN RESEARCH INSTITUTE   (United States)

^d UNIVERSITY COLLEGE LONDON   (United Kingdom)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BIZELESIN; CELL DNA; DIMER; GUANINE; NSC 615291; NSC 694501; PYRROLO[2,1 C][1,4]BENZODIAZEPINE DERIVATIVE; SJG 136; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BOLUS INJECTION; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER MODEL; CELL ASSAY; CELL KILLING; CLINICAL PROTOCOL; COLON CARCINOMA; CONTINUOUS INFUSION; CONTROLLED STUDY; DNA CROSS LINKING; DOSE RESPONSE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG DNA INTERACTION; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SENSITIVITY; GLIOMA CELL; HOLLOW FIBER; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LUNG CARCINOMA; MAXIMUM TOLERATED DOSE; MELANOMA CELL; MOUSE; NONHUMAN; OUTCOMES RESEARCH; OVARY CARCINOMA; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA; RAT; TUMOR MODEL; TUMOR VOLUME; TUMOR XENOGRAFT;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZODIAZEPINES; BENZODIAZEPINONES; CELL LINE, TUMOR; CROSS-LINKING REAGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; INDOLES; MICE; MICE, NUDE; PYRROLES; RATS; RATS, NUDE; UREA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 4644316457     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-03-2942     Document Type: Article

References (21)

1. Thurston DE. Advances in the study of pyrrolo[2,1-c][1,4]benzodiazepine (PBD) anti-tumour antibiotics. In: Neidle S, Waring MJ, editors. Topics in molecular and structural biology: molecular aspects of anticancer drug-DNA interactions. London: The Macmillan Press Ltd.; 1993. p. 54-88.
2. Puvvada MS, Forrow SA, Hartley JA, et al. Inhibition of bacteriophage T7 RNA polymerase in vitro transcription by DNA-binding pyrrolo[2,1-c][1,4] benzodiazepines. Biochemistry 1997;36:2478-84.
3. Gregson SJ, Howard PW, Jenkins TC, Kelland LR, Thurston DE. Synthesis of a novel C2/C2′-exo unsaturated pyrrolobenzodiazepine cross-linking agent with remarkable DNA binding affinity and cytotoxicity. J Chem Soc Chem Commun 1999;9:797-8.
4. Gregson SJ, Howard PW, Hartley JA, et al. Design, synthesis and evaluation of a novel pyrrolobenzodiazepine DNA-interactive agent with highly efficient crosslinking ability and potent cytotoxicity. J Med Chem 2001;44:737-48.
5. Hartley JA, Spanswick VJ, Brooks N, et al. SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum anti-tumour activity. Part 1: cellular pharmacology, in vitro and initial in vivo antitumor activity. Cancer Res 2004;64:6693-9.
6. Paull KD, Shoemaker RH, Hodes L, et al. Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm. J Natl Cancer Inst (Bethesda) 1989;81:1088-92.
7. Alley MC, Hollingshead MG, Pacula-Cox CM, et al. Efficacy evaluations of SJG-136 (NSC 694501), a novel pyrrolobenzodiazepine dimer with broad spectrum antitumor activity. Proc Am Assoc Cancer Res 2002;43:63.
8. Alley MC, Scudiero DA, Monks A, et al. Feasibility of drug screening with panels of human tumor lines using a microculture tetrazolium assay. Cancer Res 1988;48:589-601.
9. Alley MC, Pacula-Cox CM, Hollingshead MG, et al. Utility of a PVDF filter plate assay to facilitate selection of tumor cell lines for in vivo drug testing. Proc Am Assoc Cancer Res 1995;36:305.
10. nd ed. Totowa, NJ: Humana Press; 2004. p. 153-82.
11. Stinson SF, Alley MC, Koop WC, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-oriented anticancer drug screen. Anticancer Res 1992;12:1035-54.
12. Dykes DJ, Abbott BJ, Mayo JG, et al. Development of human tumor xenograft models for in vivo evaluation of new antitumor drugs. In: Huber H, Queißer W, editors. Contributions to oncology, Vol. 42. Basel, Switzerland: Karger, 1992. p. 1-12.
13. Plowman J, Dykes DJ, Hollingshead MG, Simpson-Herren L, Alley MC. Human tumor xenograft models in NCI drug development. In: Teicher BA, editor. Anticancer drug development guide: preclinical screening, clinical trials, and approval. Totowa, NJ: Humana Press; 1997. p. 101-25.
14. Anzil AP, Stavrou D, Blinzinger K, Herrlinger H, Dahme E. Ultrastructural comparison between the parenchymal cells of tumors derived from parent and hybrid lines of C1300 mouse neuroblastoma and C6 rat glioma. Cancer Res 1977;37:2236-45.
15. Ross DT, Scherf U, Eisen MB, et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 2000;24:208-9.
16. Ellison G, Klinowska T, Westwood RF, Docter E, French T, Fox JC. Further evidence to support the melanocytic origin of MDA-MB-435. Mol Pathol 2002;55:294-9.
17. Carter CA, Waud WR, Li LH, DeKoning TF, McGovren JP, Plowman J. Preclinical antitumor activity of bizelesin in mice. Clin Cancer Res 1996;2:1143-9.
18. Lee C-S, Gibson NW. DNA damage and differential cytotoxicity produced in human carcinoma cells by CC-1065 analogues, U-73,9715 and U-77,779. Cancer Res 1991;51:6586-91.
19. McGovren JP, Clarke GL, Pratt EA, DeKoning TF. Preliminary toxicity studies with the DNA-binding antibiotic CC-1065. J Antibiot (Tokyo) 1984;37:63-70.
20. Schweikart K, Gupta SI, Kwak J, Thurston D, Tomaszewski J. In vitro myelosuppression of SJG-136, a pyrrolobenzodiazepine dimer: comparison to bizelesin. Proc Am Assoc Cancer Res 2004;45:486.
21. Johnson JI, Decker S, Zaharevitz D, et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. Br J Cancer 2001;84:1424-31.